OneDigital Investment Advisors LLC Reduces Holdings in Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS)

OneDigital Investment Advisors LLC lowered its stake in shares of Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) by 31.3% during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 10,000 shares of the company’s stock after selling 4,550 shares during the quarter. OneDigital Investment Advisors LLC’s holdings in Corvus Pharmaceuticals were worth $53,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also recently modified their holdings of the stock. Vanguard Group Inc. raised its stake in Corvus Pharmaceuticals by 10.6% in the 1st quarter. Vanguard Group Inc. now owns 1,493,357 shares of the company’s stock worth $2,658,000 after acquiring an additional 142,724 shares during the last quarter. Towerview LLC increased its holdings in shares of Corvus Pharmaceuticals by 4.6% in the second quarter. Towerview LLC now owns 400,000 shares of the company’s stock valued at $728,000 after purchasing an additional 17,500 shares during the period. Samlyn Capital LLC raised its stake in shares of Corvus Pharmaceuticals by 160.7% in the second quarter. Samlyn Capital LLC now owns 6,123,021 shares of the company’s stock worth $11,144,000 after purchasing an additional 3,774,658 shares during the last quarter. Marshall Wace LLP acquired a new stake in Corvus Pharmaceuticals during the 2nd quarter valued at approximately $136,000. Finally, Cubist Systematic Strategies LLC acquired a new position in Corvus Pharmaceuticals during the second quarter valued at $44,000. 46.64% of the stock is owned by hedge funds and other institutional investors.

Corvus Pharmaceuticals Stock Performance

NASDAQ:CRVS opened at $8.95 on Friday. Corvus Pharmaceuticals, Inc. has a one year low of $1.30 and a one year high of $10.00. The stock has a market cap of $575.13 million, a PE ratio of -9.62 and a beta of 1.05. The stock has a 50 day moving average price of $7.22 and a 200 day moving average price of $4.29.

Wall Street Analyst Weigh In

Several brokerages recently weighed in on CRVS. Mizuho upgraded Corvus Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a research report on Tuesday, October 22nd. LADENBURG THALM/SH SH boosted their price objective on Corvus Pharmaceuticals from $12.00 to $21.00 and gave the company a “buy” rating in a research report on Monday, September 16th. StockNews.com cut shares of Corvus Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Thursday, October 31st. Finally, Oppenheimer boosted their price objective on Corvus Pharmaceuticals from $8.00 to $14.00 and gave the stock an “outperform” rating in a research note on Wednesday, November 13th. One analyst has rated the stock with a sell rating, three have given a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $12.83.

About Corvus Pharmaceuticals

Corvus Pharmaceuticals, Inc, a clinical stage biopharmaceutical company, focuses on the development and commercialization of immune modulator product candidates to treat solid cancers, T cell lymphomas, autoimmune, allergic, and infectious diseases. Its lead product candidate is soquelitinib (CPI-818), a selective covalent inhibitor of interleukin 2 inducible T cell kinase (ITK), which is in a multi-center Phase 1/1b clinical trial for the treatment of peripheral T cell lymphoma, solid tumors, and atopic dermatitis.